Diaz EC, Herndon DN, Porter C, Sidossis LS, Suman OE, Brsheim E
5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes
Tirzepatide Injection vs Tirzepatide ODT Tirzepatide works through both GLP-1 and GIP receptor pathways
Heat, light, or contamination exposure can cause the medication to degrade more quickly, reducing its effectiveness
A new clinical trial, co-led by endocrinologist and diabetes expert John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine has shown that the oral form of semaglutide can significantly reduce cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease, and/or chronic kidney disease
Dubois-Deruy E, Peugnet V, Turkieh A, Pinet F